-
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
Tuesday, September 7, 2021 - 9:54am | 302Read More...United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH). Related Content: In June FDA Accepted Tyvaso DPI Application Under Priority Review....
-
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
Tuesday, September 7, 2021 - 9:09am | 320Read More...Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension. Related Content: DehydraTECH Delivered Colchicine Can Potentially Treat...
-
MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension
Wednesday, June 16, 2021 - 7:26am | 197Read More...MannKind Corporation (NASDAQ: MNKD) and United Therapeutics Corporation (NASDAQ: UTHR) have announced that the FDA has accepted for review the marketing application of Tyvaso DPI (inhaled treprostinil). Under priority review status, the application seeks approval to treat...
-
Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients
Wednesday, May 19, 2021 - 3:15pm | 248Read More...Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). The data were presented at the American Thoracic Society 2021 International...
-
Chardan Reiterates Sell On Esperion, Cites 'Lack Of Visibility' And 'Possibility Of Declining Efficacy'
Tuesday, July 28, 2015 - 11:52am | 319Read More...In a report published Tuesday, Chardan Capital Markets analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ: ESPR) with a $40 price target following the release of a phase II results from Study 014 which tested ETC-1002 over six weeks in patients with...
-
5 Biotech Stocks On Deck With The FDA
Tuesday, June 30, 2015 - 1:39pm | 482Read More...Some traders like to gamble on big news events that could have a dramatic effect on a particular stock. For example, the release of a company’s earnings report could cause an underlying stock to jump to new highs or drop to significant lows. While this may not interest all investors, it does...
